146 related articles for article (PubMed ID: 1649705)
1. Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.
Lee JS; Murphy WK; Shirinian MH; Pang A; Hong WK
Cancer Chemother Pharmacol; 1991; 28(3):199-204. PubMed ID: 1649705
[TBL] [Abstract][Full Text] [Related]
2. Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer.
Lee JS; Libshitz HI; Fossella FV; Murphy WK; Pang AC; Lippman SM; Shin DM; Dimery IW; Glisson BS; Hong WK
J Natl Cancer Inst; 1992 Jul; 84(13):1039-40. PubMed ID: 1318977
[No Abstract] [Full Text] [Related]
3. Edatrexate studies in non-small cell lung cancer.
Gralla RJ
Lung Cancer; 1995 Apr; 12 Suppl 1():S187-91. PubMed ID: 7551928
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
5. Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer.
Lee JS; Libshitz HI; Fossella FV; Murphy WK; Pang AC; Lippman SM; Shin DM; Dimery IW; Glisson BS; Hong WK
Cancer; 1991 Sep; 68(5):959-64. PubMed ID: 1655220
[TBL] [Abstract][Full Text] [Related]
6. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
Kindler HL; Belani CP; Herndon JE; Vogelzang NJ; Suzuki Y; Green MR
Cancer; 1999 Nov; 86(10):1985-91. PubMed ID: 10570422
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck.
Huber MH; Dimery IW; Benner SE; Lippman SM; Shirinian M; Esparaz B; Frenning D; Guillory-Perez C; Hong WK
Invest New Drugs; 1994; 12(4):327-31. PubMed ID: 7775135
[TBL] [Abstract][Full Text] [Related]
8. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
9. Edatrexate, an antifolate with antitumor activity: a review.
Grant SC; Kris MG; Young CW; Sirotnak FM
Cancer Invest; 1993; 11(1):36-45. PubMed ID: 8422595
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
Gandara DR; Edelman MJ; Crowley JJ; Lau DH; Livingston RB
Cancer Chemother Pharmacol; 1997; 41(1):75-8. PubMed ID: 9443617
[TBL] [Abstract][Full Text] [Related]
11. High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.
Pisters KM; Tyson LB; Tong W; Fleisher M; Miller VA; Grant SC; Pfister DG; Rigas JR; Densmore CL; Krol G; Heelan RT; Sirotnak FM; Bertino JR; Kris MG
Clin Cancer Res; 1996 Nov; 2(11):1819-24. PubMed ID: 9816135
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
13. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
Sirotnak FM; Otter GM; Schmid FA
Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
[TBL] [Abstract][Full Text] [Related]
14. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis.
Perez EA; Hack FM; Webber LM; Chou TC
Cancer Chemother Pharmacol; 1993; 33(3):245-50. PubMed ID: 8269606
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma.
Pazdur R; Moore DF; Bready B; Giannone L; Maldonado A; Lin YG; Fueger RH; Winn RJ; Levin B
Ann Oncol; 1994 Sep; 5(7):646-8. PubMed ID: 7527654
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent edatrexate toxicity.
Perez EA
J Clin Oncol; 1996 Jan; 14(1):322-3. PubMed ID: 8558215
[No Abstract] [Full Text] [Related]
18. Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate.
Jolivet J; Jansen G; Peters GJ; Pinard MF; Schornagel JH
Biochem Pharmacol; 1994 Feb; 47(4):659-65. PubMed ID: 7510479
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy.
Edelman MJ; Gandara DR; Perez EA; Lau D; Lauder I; Turrell C; Uhrich M; Meyers F
Invest New Drugs; 1998; 16(1):69-75. PubMed ID: 9740546
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer.
Souhami RL; Rudd RM; Spiro SG; Allen R; Lamond P; Harper PG
Cancer Chemother Pharmacol; 1992; 30(6):465-8. PubMed ID: 1327568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
